<VariationArchive VariationID="8302" VariationName="NM_000156.6(GAMT):c.299_311dup (p.Arg105fs)" VariationType="Duplication" Accession="VCV000008302" Version="25" RecordType="classified" NumberOfSubmissions="12" NumberOfSubmitters="12" DateLastUpdated="2024-06-23" DateCreated="2015-02-13" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="23341" VariationID="8302">
      <GeneList>
        <Gene Symbol="GAMT" FullName="guanidinoacetate N-methyltransferase" GeneID="2593" HGNC_ID="HGNC:4136" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1397026" stop="1401542" display_start="1397026" display_stop="1401542" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1397024" stop="1401568" display_start="1397024" display_stop="1401568" Strand="-" />
          </Location>
          <OMIM>601240</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000156.6(GAMT):c.299_311dup (p.Arg105fs)</Name>
      <CanonicalSPDI>NC_000019.10:1399808:GGGGCCCAGTCCCGG:GGGGCCCAGTCCCGGGGCCCAGTCCCGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>19p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1399808" stop="1399809" display_start="1399808" display_stop="1399809" variantLength="13" positionVCF="1399808" referenceAlleleVCF="T" alternateAlleleVCF="TGGGGCCCAGTCCC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1399807" stop="1399808" display_start="1399807" display_stop="1399808" variantLength="13" positionVCF="1399807" referenceAlleleVCF="T" alternateAlleleVCF="TGGGGCCCAGTCCC" />
      </Location>
      <OtherNameList>
        <Name>NM_000156.6(GAMT):c.299_311dup</Name>
        <Name>p.Arg105fs</Name>
      </OtherNameList>
      <ProteinChange>R105fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.1399811_1399823dup" Assembly="GRCh38">
            <Expression>NC_000019.10:g.1399811_1399823dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.1399810_1399822dup" Assembly="GRCh37">
            <Expression>NC_000019.9:g.1399810_1399822dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009785.1" sequenceAccession="NG_009785" sequenceVersion="1" change="g.6733_6745dup">
            <Expression>NG_009785.1:g.6733_6745dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.6" sequenceAccession="NM_000156" sequenceVersion="6" change="c.299_311dup" MANESelect="true">
            <Expression>NM_000156.6:c.299_311dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000147.1" sequenceAccession="NP_000147" sequenceVersion="1" change="p.Arg105fs">
            <Expression>NP_000147.1:p.Arg105fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_138924.3" sequenceAccession="NM_138924" sequenceVersion="3" change="c.299_311dup">
            <Expression>NM_138924.3:c.299_311dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_620279.1" sequenceAccession="NP_620279" sequenceVersion="1" change="p.Arg105fs">
            <Expression>NP_620279.1:p.Arg105fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.5" sequenceAccession="NM_000156" sequenceVersion="5" change="c.299_311dup">
            <Expression>NM_000156.5:c.299_311dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.4" sequenceAccession="NM_000156" sequenceVersion="4" change="c.299_311dup">
            <Expression>NM_000156.4:c.299_311dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.5" sequenceAccession="NM_000156" sequenceVersion="5" change="c.299_311dupGGGACTGGGCCCC">
            <Expression>NM_000156.5:c.299_311dupGGGACTGGGCCCC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="601240.0002" DB="OMIM" />
        <XRef Type="rs" ID="80338736" DB="dbSNP" />
        <XRef ID="CA340767" DB="ClinGen" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000156.6(GAMT):c.299_311dup (p.Arg105fs) AND Deficiency of guanidinoacetate methyltransferase" Accession="RCV000008800" Version="17">
        <ClassifiedConditionList TraitSetID="2278">
          <ClassifiedCondition DB="MedGen" ID="C0574080">Deficiency of guanidinoacetate methyltransferase</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2022-06-06" SubmissionCount="8">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000156.6(GAMT):c.299_311dup (p.Arg105fs) AND Cerebral creatine deficiency syndrome" Accession="RCV000534459" Version="10">
        <ClassifiedConditionList TraitSetID="16862">
          <ClassifiedCondition DB="MedGen" ID="C5244016">Cerebral creatine deficiency syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-24" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000156.6(GAMT):c.299_311dup (p.Arg105fs) AND not provided" Accession="RCV001787373" Version="2">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-11-29" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000156.6(GAMT):c.299_311dup (p.Arg105fs) AND Inborn genetic diseases" Accession="RCV002433449" Version="2">
        <ClassifiedConditionList TraitSetID="25797">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-07-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-06" NumberOfSubmissions="12" NumberOfSubmitters="12" DateCreated="2015-02-13" MostRecentSubmission="2024-06-17">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15108290</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19027335</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23234264</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23660394</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24071436</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24268530</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24276113</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29506905</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8651275</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/b134da76-0dcf-48dd-ae4e-1058f82a5e7e</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="2278" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2252" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
                <XRef ID="Guanidinoacetate+Methyltransferase+Deficiency/3202" DB="Genetic Alliance" />
                <XRef ID="124239003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CEREBRAL CREATINE DEFICIENCY SYNDROME 2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0005" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCDS2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2578" />
                <XRef ID="2578" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Guanidinoacetate, Guanidinoacetate Methyltransferase Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Algorithm, GAMT Deficiency: Elevated Guanidinoacetate, 2022</CitationText>
              </Citation>
              <XRef ID="382" DB="Orphanet" />
              <XRef ID="C0574080" DB="MedGen" />
              <XRef ID="MONDO:0012999" DB="MONDO" />
              <XRef Type="MIM" ID="612736" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="16862" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16661" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cerebral creatine deficiency syndrome</ElementValue>
                <XRef ID="MONDO:0000456" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Creatine deficiency syndromes</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCAD</ElementValue>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CDS</ElementValue>
                <XRef ID="79172" DB="Orphanet" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18952" />
                <XRef ID="18952" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <XRef ID="79172" DB="Orphanet" />
              <XRef ID="C5244016" DB="MedGen" />
              <XRef ID="MONDO:0000456" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25797" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="29010" SubmissionDate="2015-02-11" DateLastUpdated="2015-02-13" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="601240.0002_CEREBRAL CREATINE DEFICIENCY SYNDROME 2" title="GAMT, 13-BP DUP, NT309_CEREBRAL CREATINE DEFICIENCY SYNDROME 2" />
        <ClinVarAccession Accession="SCV000029010" DateUpdated="2015-02-13" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1996-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">For discussion of the 13-bp duplication in exon 2 of the GAMT gene (309dup13) that was found in compound heterozygous state in a patient with a severe neurologic syndrome due to cerebral creatine deficiency syndrome-2 (CCDS2; 612736) by Stockler et al. (1996), see 601240.0001.</Attribute>
              <Citation>
                <ID Source="PubMed">8651275</ID>
              </Citation>
              <XRef DB="OMIM" ID="612736" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <Name>GAMT, 13-BP DUP, NT309</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">13-BP DUP, NT309</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="601240.0002" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CEREBRAL CREATINE DEFICIENCY SYNDROME 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1796032" SubmissionDate="2019-04-24" DateLastUpdated="2019-06-02" DateCreated="2019-06-02">
        <ClinVarSubmissionID localKey="NM_000156.4:c.299_311dup13|MedGen:C0574080" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000919411" DateUpdated="2019-06-02" DateCreated="2019-06-02" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-02-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24268530</ID>
          </Citation>
          <Comment>Variant summary: GAMT c.299_311dup13 (p.Arg105GlyfsX26) results in a frameshift generating a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (eg. c.491dupG (p.Val165fsX26)). The variant was found at a frequency of 5.2e-05 (11/210322) control chromosomes in gnomAD, predominantly observed in the European (Non-Finnish) subpopulation (11/90660) with a frequency of 0.00012. This frequency is not significantly higher than expected for a pathogenic variant in GAMT causing Guanidinoactetate methyltransferase deficiency (0.00012 vs 0.0011), allowing no conclusion about variant significance. c.299_311dup13 has been reported in the literature in multiple individuals affected with Guanidinoactetate methyltransferase deficiency either in homozygosity (Cheillan 2012) or in heterozygous form with other pathogenic (or likely pathogenic) GAMT variants in trans (e.g. Dhar 2009, Stockler 2014). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2017, and both of them classified it as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.4:c.299_311dup13</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0574080" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5494893</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3896965" SubmissionDate="2021-11-02" DateLastUpdated="2022-02-02" DateCreated="2021-11-05">
        <ClinVarSubmissionID localKey="04031394-ebb5-4d34-82c0-af36ee89acbe" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001999926" DateUpdated="2022-02-02" DateCreated="2021-11-05" Type="SCV" Version="2" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The p.Arg105fs variant in GAMT has been reported in 5 individuals with cerebral creatine deficiency syndrome (PMID: 8651275, 19027335, 23234264, 23660394, 24268530), segregated with disease in 2 affected relatives from 2 families (PMID: 23234264, 24268530), and has been identified in in 0.01% (11/93592) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs779679242). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of the 5 affected individuals, at least 1 of those was a homozygote and 2 were compound heterozygotes that carried a reported pathogenic variant in trans, which increases the likelihood that the p.Arg105fs variant is pathogenic (Variation ID: 21065; PMID: 8651275, 19027335, 23234264, 23660394, 24268530). This variant has also been reported in ClinVar (Variation ID#: 8302) and has been interpreted as pathogenic by Integrated Genetics (Laboratory Corporation of America), OMIM, Invitae, and GeneReviews. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 105 and leads to a premature termination codon 26 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the GAMT gene is a strongly established disease mechanism in autosomal recessive cerebral creatine deficiency syndrome. The phenotype of individuals homozygous or compound heterozygous for this variant is highly specific for cerebral creatine deficiency syndrome based on strict biochemical investigations consistent with disease (PMID: 23660394, 8651275, 19027335, 23660394). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive cerebral creatine deficiency syndrome. ACMG/AMP Criteria applied: PVS1, PM3_strong, PM2_supporting, PP4 (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Abbrev="ACMG, 2015" Type="practice guideline">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000156.6(GAMT):c.299_311dup</Name>
            <Name>p.Arg105fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.10:g.1399811_1399823dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0000456" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10607670</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5461406" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000156.6:c.299_311dup|OMIM:612736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002813872" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-01-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.299_311dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3984042" SubmissionDate="2021-12-08" DateLastUpdated="2023-03-04" DateCreated="2021-12-12">
        <ClinVarSubmissionID localKey="GDXSV:216704" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002031066" DateUpdated="2023-03-04" DateCreated="2021-12-12" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 19027335, 8651275, 23660394, 29655203, 23234264)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:348476</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.4:c.299_311dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_74_20211208054205</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7848396" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000156.6:c.299_311dup|OMIM:612736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004198577" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.299_311dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4083168" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000156.6:c.299_311dup|Guanidinoacetate methyltransferase deficiency" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002087040" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-22">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.299_311dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Guanidinoacetate methyltransferase deficiency</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="5080865" SubmissionDate="2022-11-09" DateLastUpdated="2022-11-13" DateCreated="2022-11-13">
        <ClinVarSubmissionID localKey="b134da76-0dcf-48dd-ae4e-1058f82a5e7e" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002600154" DateUpdated="2022-11-13" DateCreated="2022-11-13" Type="SCV" Version="1" SubmitterName="ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen" OrgID="508816" OrganizationCategory="consortium" OrgAbbreviation="ClinGen CCDS VCEP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-06">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/b134da76-0dcf-48dd-ae4e-1058f82a5e7e</URL>
          </Citation>
          <Comment>The NM_000156.6:c.299_311dup (p. Arg105GlyfsTer26) in GAMT is a frameshift variant predicted to cause a premature stop codon in biologically relevant 3/6 leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). At least 4 probands with biochemical and clinical features consistent with GAMT deficiency have been reported, including patients with elevated plasma guanidinoacetate, and absent creatine peak and evidence of guanidinoacetate peak on magnetic resonance spectroscopy (PMIDs 8651275, 19027335, 19388150, 23660394, 29506905) (PP4_Strong). These patients include one homozygote (with a homozygous affected sibling) (PMID 23234264; 0.5 points; possibly same patient reported in PMID 29506905); and a proband who is compound heterozygous for the variant and c.327G&gt;A (pathogenic based on assessment by the ClinGen CCDS VCEP), confirmed in trans (PMID 8651275, 19027335, 24268530) (PM3). Another patient is compound heterozygous for the variant and c.233T&gt;A (p.Val78Glu)(PMID 23660394), and another patient and her affected sibling are compound heterozygous for the variant and c.403G&gt;A (p.Asp135Asn) (PMID 19388150), The in trans data from the latter patients will be used in the analysis of p.Val78Glu and p.Asp135Asn and is not included here to avoid circular logic (PM3_Strong). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001175 in the European non-Finnish population, which is lower than the ClinGen CCDS VCEP's threshold for PM2_Supporting (&lt;0.0004), meeting this criterion (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 8302). In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency. GAMT-specific ACMG/AMP codes met, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes VCEP (Specifications Version 1.1.0): PVS1, PM3, PP4_Strong, PM2_Supporting. (Classification approved by the ClinGen CCDS VCEP on June 6, 2022).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen_CCDS_ACMG_Specifications_GAMT_v1.1</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8u1i2ttx/clingen_ccds_acmg_specifications_gamt_v1.1.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000156.6(GAMT):c.299_311dup</Name>
            <Name>p.Arg105fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.10:g.1399811_1399823dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0012999" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12271376</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5413210" SubmissionDate="2022-12-21" DateLastUpdated="2022-12-24" DateCreated="2022-12-24">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000156_5_GAMT_c_299_311dupGGGACTGGGCCCC" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002768340" DateUpdated="2022-12-24" DateCreated="2022-12-24" Type="SCV" Version="1" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24071436</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24276113</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29506905</ID>
          </Citation>
          <Comment>Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with cerebral creatine deficiency syndrome 2 (MIM#612736). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) &lt;0.01 for a recessive condition (11 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (DECIPHER). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been observed in multiple individuals with cerebral creatine deficiency (also known as GAMT deficiency, ClinVar, PMIDs: 24071436, 24276113, 29506905). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_12912</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.5:c.299_311dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_38</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3967130" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="d7c775c27db5d2169091f66ecb5b4e770c7e798c117d6d2e681cfef697e782b9|OMIM:612736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002024175" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.299_311dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1257774" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="568203|MedGen:CN227588" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000659565" DateUpdated="2024-02-20" DateCreated="2017-12-26" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15108290</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8651275</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19027335</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23234264</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23660394</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Arg105Glyfs*26) in the GAMT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GAMT are known to be pathogenic (PMID: 15108290). This variant is present in population databases (rs756953118, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with guanidinoacetatemethyltransferase (GAMT) deficiency (PMID: 8651275, 19027335, 23234264, 23660394). It has also been observed to segregate with disease in related individuals. This variant is also known as 309ins13 or c.297_309dup. ClinVar contains an entry for this variant (Variation ID: 8302). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.1399807_1399808insGGGGCCCAGTCCC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN227588" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5237594" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a406204|MedGen:C0950123" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002746400" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-07-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19027335</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23234264</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23660394</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8651275</ID>
          </Citation>
          <Comment>The c.299_311dup13 variant, located in coding exon 2 of the GAMT gene, results from a duplication of GGGACTGGGCCCC at nucleotide position 299, causing a translational frameshift with a predicted alternate stop codon (p.R105Gfs*26). This alteration has been detected as homozygous in two individuals with GAMT deficiency (Cheillan D, Orphanet J Rare Dis 2012 Dec;7:96). In addition, this alteration has been detected in conjunction with other GAMT alterations in several individuals with GAMT deficiency and creatine deficiency syndromes (Comeaux MS, Mol. Genet. Metab. 2013 Jul;109(3):260-8; Dhar SU, Mol. Genet. Metab. 2009 Jan;96(1):38-43; St&amp;ouml;ckler S,Am. J. Hum. Genet. 1996 May;58(5):914-22). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.5:c.299_311dupGGGACTGGGCCCC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1257774" TraitType="Disease" MappingType="XRef" MappingValue="CN227588" MappingRef="MedGen">
        <MedGen CUI="C5244016" Name="Cerebral creatine deficiency syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7848396" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3896965" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0000456" MappingRef="MONDO">
        <MedGen CUI="C5244016" Name="Cerebral creatine deficiency syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5413210" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3984042" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="29010" TraitType="Disease" MappingType="Name" MappingValue="CEREBRAL CREATINE DEFICIENCY SYNDROME 2" MappingRef="Preferred">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5461406" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1796032" TraitType="Disease" MappingType="Name" MappingValue="Deficiency of guanidinoacetate methyltransferase" MappingRef="Preferred">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5080865" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0012999" MappingRef="MONDO">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3967130" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5237594" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4083168" TraitType="Disease" MappingType="Name" MappingValue="Guanidinoacetate methyltransferase deficiency" MappingRef="Preferred">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="2" DateDeleted="2022-07-21">SCV000040466</Accession>
        <Description>This variant is no longer cited in the GeneReview and has been deleted.</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

